- Home
- NEO vs GERN Comparison
NEO vs GERN Comparison
Compare NEO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEO | GERN |
|---|---|---|
| Founded | 2001 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEO | GERN |
|---|---|---|
| Price | $8.29 | $1.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $13.38 | $2.17 |
| AVG Volume (30 Days) | 2.2M | ★ 15.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | $26.91 |
| Revenue Next Year | $9.73 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $1.04 |
| 52 Week High | $13.74 | $2.01 |
Technical Indicators
Market Signals| Indicator | NEO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 32.86 |
| Support Level | $7.50 | $1.24 |
| Resistance Level | $8.84 | $1.49 |
| Average True Range (ATR) | 0.55 | 0.09 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 4.29 | 0.00 |
Price Performance
Historical ComparisonAbout NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.